title: Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
abstract: OBJECTIVE
  To determine the activity of carboplatin in patients with ovarian cancer who progressed on taxane (paclitaxel or docetaxel) therapy.
  
  
  METHODS
  Thirty-three patients with ovarian cancers refractory to platinum and taxane therapy were treated with single-agent carboplatin reinduction once the disease progressed on a taxane. The starting dose of carboplatin was 300 mg/m2 at 28-day intervals.
  
  
  RESULTS
  Patients were a median age of 56 years (range, 31 to 80), had a median Zubrod performance status of 1 (range, 0 to 2) and had received a median of three prior chemotherapy regimens (range, two to eight) and one pretaxane platinum regimen (range, one to three). Twenty-six patients had a platinum-free interval of at least 12 months at the time of posttaxane re-treatment with carboplatin. There were seven of 33 (21%) partial responses, with a median duration of 7+ months (range, 2+ to 12+). Responses were noted only in patients with at least a 12-month platinum-free interval and an initial sensitivity to a taxane. The therapy was well tolerated and neurotoxicity was absent.
  
  
  CONCLUSIONS
  A subset of patients with platinum-refractory disease that initially responded to a taxane and who eventually have a platinum-free interval of at least 1 year may respond to carboplatin reinduction. This finding may be secondary to paclitaxel or docetaxel therapy that leads to the reversal of platinum resistance, or the prolonged platinum-free interval permits the loss of resistance to platinum by the tumor. Carboplatin reinduction should be considered in the treatment of patients whose ovarian cancer progresses after an initial sensitivity to a taxane and who had a prolonged platinum-free interval.
authors.affiliation: Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: J
authors.initials: J
authors.lastname: Kavanagh
authors.forename: D
authors.initials: D
authors.lastname: Tresukosol
authors.forename: C
authors.initials: C
authors.lastname: Edwards
authors.forename: R
authors.initials: R
authors.lastname: Freedman
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez de Leon
authors.forename: A
authors.initials: A
authors.lastname: Fishman
authors.forename: R
authors.initials: R
authors.lastname: Mante
authors.forename: M
authors.initials: M
authors.lastname: Hord
authors.forename: A
authors.initials: A
authors.lastname: Kudelka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D001952:Bridged-Ring Compounds; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D043823:Taxoids
chemical_list: D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D016190:Carboplatin; D002945:Cisplatin